Study Overview: This study is for people with advanced non-small cell lung cancer (NSCLC). NSCLC is a type of lung cancer that has spread to other parts of the body. The study is testing a treatment called BAY2927088. This medicine is designed to block abnormal proteins called EGFR and HER2 that help cancer grow. By blocking these proteins, the medicine may help stop the cancer from spreading.
What to Expect: If you join the study, you will take the medicine in cycles of 3 weeks. You might take it once or twice a day. You will have up to 5 visits each cycle for tests and check-ups. These include blood and urine tests, CT or MRI scans to check your cancer, and questions about how you're feeling.
- Study Length: You will stay in the study as long as it's helping and safe for you.
- Visits: Up to 5 visits per cycle for tests and check-ups.
- Safety and Risks: The study will check for any side effects, which are also called adverse events.
Eligibility: To join, you must have advanced NSCLC with specific mutations and meet other health criteria. You shouldn’t have recent treatments that could interfere with the study.